Matthew Shea
Stock Analyst at Needham
(2.96)
# 2,616
Out of 4,423 analysts
36
Total ratings
50%
Success rate
6.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Shea
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TOI The Oncology Institute | Reiterated: Buy | $5 → $7 | $5.26 | +33.08% | 7 | Jun 17, 2026 | |
| ASTH Astrana Health | Rated: Buy | $30 → $41 | $39.17 | +4.67% | 3 | May 8, 2026 | |
| EVH Evolent Health | Reiterated: Buy | $4 → $5 | $4.49 | +11.36% | 11 | May 7, 2026 | |
| AGL agilon health | Reiterated: Hold | n/a | $113.80 | - | 8 | May 7, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $30 | $23.67 | +26.74% | 7 | May 7, 2026 |
The Oncology Institute
Jun 17, 2026
Reiterated: Buy
Price Target: $5 → $7
Current: $5.26
Upside: +33.08%
Astrana Health
May 8, 2026
Rated: Buy
Price Target: $30 → $41
Current: $39.17
Upside: +4.67%
Evolent Health
May 7, 2026
Reiterated: Buy
Price Target: $4 → $5
Current: $4.49
Upside: +11.36%
agilon health
May 7, 2026
Reiterated: Hold
Price Target: n/a
Current: $113.80
Upside: -
Privia Health Group
May 7, 2026
Reiterated: Buy
Price Target: $30
Current: $23.67
Upside: +26.74%